文献速递头颈部肿瘤放疗

DAHANCA19:EGFR抑制剂扎芦木单抗联合根治性放化疗治疗头颈鳞癌的III期随机研究

DAHANCA19: A randomized phase III study of primary curative (chemo)-radiotherapy and the EGFR-inhibitor zalutumumab for squamous cell carcinoma of the head and neck.
PubMed 文献 · Radiother Oncol · 2025-04-19

DAHANCA19是一项III期随机研究,纳入608例口腔、咽及喉部活检证实的头颈鳞癌患者,随机分为对照组(加速放疗联合尼莫拉唑,III-IV期加顺铂)和扎芦木单抗组(对照组方案加扎芦木单抗8 mg/kg)。中位随访59个月,扎芦木单抗组5年局部区域失败率为24%,对照组为18%(HR 1.16,95%CI 0.84-1.59),疾病特异性生存HR 1.04(95%CI 0.73-1.50),总生存HR 1.21(95%CI 0.91-1.61)。结论:在根治性放化疗联合尼莫拉唑基础上加用扎芦木单抗未改善局部区域控制、疾病特异性生存或总生存。

要点

  • 扎芦木单抗组5年局部区域失败率24% vs 对照组18%(HR 1.16,95%CI 0.84-1.59)。
  • 疾病特异性生存HR 1.04(95%CI 0.73-1.50),总生存HR 1.21(95%CI 0.91-1.61)。
  • 扎芦木单抗的效应未受HPV/p16状态影响。

核心结论

  • 在根治性放化疗联合尼莫拉唑基础上加用扎芦木单抗未增加局部区域控制,也未改善疾病特异性生存或总生存。

研究设计与样本

  • 对照组接受主要為66-68 Gy、2 Gy/次、6次/周的加速放疗,联合每日尼莫拉唑乏氧增敏;III-IV期癌加每周顺铂40 mg/m2。
  • 扎芦木单抗组与对照组相同,加扎芦木单抗8 mg/kg,首剂于治疗开始前一周给予,放疗期间每周继续。
  • 分析按意向性治疗进行,主要终点为局部区域失败,次要终点为疾病特异性生存和总生存。

主要发现

  • 对照组307例,扎芦木单抗组301例,中位随访59个月,患者和肿瘤参数均衡。
  • 5年局部区域失败率扎芦木单抗组24% vs 对照组18%(HR 1.16,95%CI 0.84-1.59)。
  • 疾病特异性生存HR 1.04(95%CI 0.73-1.50),总生存HR 1.21(95%CI 0.91-1.61)。
  • 扎芦木单抗的效应未受HPV/p16状态影响。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Antibodies against the Epidermal Growth Factor receptor is suggested to decrease tumour failure and increase survival rates of patients (pts) with Head and Neck Squamous Cell Carcinomas (HNSCC) when combined with radiotherapy. This study aimed to evaluate if concurrent treatment with the EGFR inhibitor zalutumumab during (chemo-)radiotherapy improved outcome in pts with HNSCC. MATERIALS AND METHODS: Overall, 608 eligible pts with biopsy-verified HNSCC of the oral cavity, pharynx and larynx were accrued November 2007 to June 2012. Pts were randomized to a control-arm of primary accelerated radiotherapy predominantly 66-68 Gy, 2 Gy/fraction, 6fx/week and concomitant daily hypoxic radiosensitisation with nimorazole. St. III-IV carcinomas received weekly cisplatin 40 mg/m2 in addition to nimorazole. The zalutumumab-arm was identical to the control-arm plus zalutumumab 8 mg/kg. First dose was given the week before start of treatment and continued weekly during radiotherapy. Analyses were performed as intention-to-treat. Primary endpoint was loco-regional failure. Secondary endpoints were disease-specific survival and overall survival. RESULTS: In total, 307 pts were in the control-arm and 301 in the zalutumumab-arm. Median follow-up was 59 months. Patient and tumour parameters were well balanced. The 5-year loco-regional failure rate was 24 % in the zalutumumab-arm and 18 % in the control-arm; Hazard Ratio (HR) 1.16 (95 % CI 0.84-1.59); disease-specific survival; HR 1.04 (95 % CI 0.73-1.50) and overall survival; HR 1.21, (0.91-1.61). Effect of zalutumumab was not influenced by HPV/p16 status. CONCLUSION: Addition of concomitant zalutumumab to primary (chemo-)radiotherapy and concomitant nimorazole for HNSCC did not increase loco-regional control nor disease-specific or overall survival.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Eriksen JG, Maare C, Johansen J, et al. DAHANCA19: A randomized phase III study of primary curative (chemo)-radiotherapy and the EGFR-inhibitor zalutumumab for squamous cell carcinoma of the head and neck. Radiother Oncol. 2025. PMID: 40258418. doi:10.1016/j.radonc.2025.110899

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。